Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
- Status
- TERMINATED
- Phase
- PHASE2
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
- Status
- TERMINATED
- Phase
- PHASE2
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
- Status
- COMPLETED
- Phase
- PHASE2
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
A Study of a Personalized Neoantigen Cancer Vaccine
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
- Status
- SUSPENDED
- Phase
- PHASE2/PHASE3
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2